Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial entities : Astellas pharma inc save search
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
Published: 2023-10-22 (Crawled : 16:20) - prnewswire.com
ALPMF | News | $9.594 43.47% 2.2K
|
Health Technology
| Email alert
Add to watchlist
SGEN | $228.74 0.1% 20M
|
Health Technology
| Email alert
Add to watchlist
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
| Email alert
Add to watchlist
ev-302 padcev bladder cancer trial
Bipolar Disorder Landscape Report with DLI's Clinical Trial Assessment, Product Portfolio Extension, and Post Launch Services | Disease Landscape Insights
Published: 2023-10-09 (Crawled : 14:00) - prnewswire.com
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -0.04%
H: 0.77%
C: 0.7%
disease services report trial
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
Published: 2023-09-22 (Crawled : 09:00) - prnewswire.com
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -0.56%
H: 1.48%
C: 1.12%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 3.59%
H: 0.09%
C: -0.05%
ev-302 padcev bladder cancer trial
Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause
Published: 2023-06-28 (Crawled : 08:00) - biospace.com/
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 1.2%
H: 0.26%
C: -0.2%
positive treatment topline trial results
Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause
Published: 2023-06-27 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 1.2%
H: 0.26%
C: -0.2%
positive treatment topline trial results
Results from Astellas' Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet
Published: 2023-04-14 (Crawled : 23:00) - prnewswire.com
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
| Email alert
Add to watchlist
ALPMF | News | $9.594 43.47% 2.2K
|
Health Technology
| Email alert
Add to watchlist
lancet trial results
Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series
Published: 2023-03-21 (Crawled : 22:00) - prnewswire.com
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 0.57%
H: 1.35%
C: 0.43%
glow asco positive trial
Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib
Published: 2023-03-09 (Crawled : 07:00) - prnewswire.com
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 0.36%
H: 0.14%
C: -0.99%
topline trial results
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease
Published: 2023-01-20 (Crawled : 07:00) - prnewswire.com
ALPMF | News | $9.594 43.47% 2.2K
|
Health Technology
|
| O: -1.43%
H: 0.0%
C: 0.0%
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -0.07%
H: 1.33%
C: 1.26%
at845 treatment fda disease lifted trial
Astellas to Present Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers Symposium
Published: 2023-01-19 (Crawled : 15:20) - biospace.com/
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 0.2%
H: 0.0%
C: -0.46%
symposium trial asco positive
Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers
Published: 2022-12-15 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 1.61%
H: 0.0%
C: -1.14%
treatment glow trial her2- her2
Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers
Published: 2022-11-16 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 1.56%
H: 0.0%
C: -1.41%
treatment trial her2- her2
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
Published: 2022-09-12 (Crawled : 13:20) - biospace.com/
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 0.71%
H: 0.14%
C: -1.05%
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.9%
H: 1.17%
C: 0.03%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: -3.57%
padcev trial results cancer
Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials
Published: 2022-07-06 (Crawled : 13:00) - biospace.com/
ALPMF | News | $9.594 43.47% 2.2K
|
Health Technology
|
| O: 2.63%
H: 0.0%
C: 0.0%
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 0.58%
H: 1.66%
C: 0.38%
trials zenith cancer trial
Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease
Published: 2022-06-27 (Crawled : 08:00) - biospace.com/
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -1.2%
H: 0.0%
C: -0.37%
at845 fda disease trial update
Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease
Published: 2022-06-26 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -1.2%
H: 0.0%
C: -0.37%
at845 fda disease trial update
ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Published: 2022-01-19 (Crawled : 13:00) - biospace.com/
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -0.27%
H: 0.51%
C: 0.21%
EPIX | $6.67 -5.66% -6.0% 36K
|
Health Technology
|
| O: -5.58%
H: 5.2%
C: -1.65%
epi-7386 prostate cancer trial phase 1 cancer
Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Published: 2021-10-12 (Crawled : 13:00) - biospace.com/
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 2.57%
H: 0.0%
C: -2.82%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.22%
H: 2.27%
C: 1.35%
treatment cancer trial enroll
Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Published: 2021-10-12 (Crawled : 12:00) - prnewswire.com
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 2.57%
H: 0.0%
C: -2.82%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.22%
H: 2.27%
C: 1.35%
treatment cancer trial enroll
Astellas to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2™ Trial in Oral Session at The North American Menopause Society 2021 Annual Meeting
Published: 2021-09-22 (Crawled : 14:00) - biospace.com/
ALPMF | News | $9.594 43.47% 2.2K
|
Health Technology
| Email alert
Add to watchlist
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
| Email alert
Add to watchlist
phase 3 trial
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
AGBA | $1.02 155.0% 60.78% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 900K
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.